Rennova Health Inc (RNVA)

[Werbe]

Preferred series N and Preferred series O converted into 7 billion plus this last quarter, worst part this happened only by converting 640 preferred shares. That equals out to each Preferred share converting into 11 million shares apiece. There are like 11,000 shares of preferred left just between those two class of preferred.

During the three months ended September 30, 2023, the holders converted 180 shares of their Series O Preferred Stock with a stated value of $0.2 million into 2.0 billion shares of the Company’s common stock. No shares of Series O Preferred Stock were converted during the three months ended September 30, 2022. During the nine months ended September 30, 2023 and 2022, the holders converted 220.5 and 638 shares, respectively, of their Series O Preferred Stock with a stated value of $0.2 million and $0.6 million, respectively, into 2.5 billion and 6.7 billion shares of the Company’s common stock, respectively. On September 30, 2023, 8,464.59 shares of Series O Preferred Stock remained outstanding and were convertible into 94.1billion shares of the Company’s common stock.

During the three months ended September 30, 2023, the holders converted 460.53 shares of their Series N Preferred Stock with a stated value of $0.5 million into 5.1 billion shares of the Company’s common stock. No shares of Series N Preferred Stock were converted during the three months ended September 30, 2022. During the nine months ended September 30, 2023 and 2022, the holders converted 496.53 shares and 2,352 shares, respectively, of their Series N Preferred Stock with a stated value of $0.5 million and $2.4 million, respectively, into 5.5 billion and 8.4 billion shares, respectively, of the Company’s common stock. On September 30, 2023, 2,403.78 shares of Series N Preferred Stock remained outstanding and were convertible into 26.7 billion shares of the Company’s common stock.